About lyell immunopharma inc - LYEL
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
LYEL At a Glance
Lyell Immunopharma, Inc.
201 Haskins Way
South San Francisco, California 94080
| Phone | 1-650-695-0677 | Revenue | 36.00K | |
| Industry | Biotechnology | Net Income | -274,448,000.00 | |
| Sector | Health Technology | Employees | 161 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LYEL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14,614.515 |
| Price to Book Ratio | 2.635 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.716 |
| Enterprise Value to Sales | 9,163.793 |
| Total Debt to Enterprise Value | 0.155 |
LYEL Efficiency
| Revenue/Employee | 223.602 |
| Income Per Employee | -1,704,645.963 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.00 |
LYEL Liquidity
| Current Ratio | 5.281 |
| Quick Ratio | 5.281 |
| Cash Ratio | 5.003 |
LYEL Profitability
| Gross Margin | -31,952.778 |
| Operating Margin | -566,038.889 |
| Pretax Margin | -762,355.556 |
| Net Margin | -762,355.556 |
| Return on Assets | -66.06 |
| Return on Equity | -86.985 |
| Return on Total Capital | -91.728 |
| Return on Invested Capital | -75.821 |
LYEL Capital Structure
| Total Debt to Total Equity | 20.545 |
| Total Debt to Total Capital | 17.044 |
| Total Debt to Total Assets | 14.996 |
| Long-Term Debt to Equity | 16.89 |
| Long-Term Debt to Total Capital | 14.011 |